ZA941197B - Transmucosal delivery of macromolecular drugs - Google Patents

Transmucosal delivery of macromolecular drugs

Info

Publication number: ZA941197B
Authority: ZA; South Africa
Prior art keywords: macromolecular; polymer; drug; enhancer; macromolecular drugs
Prior art date: 1993-02-22

Application number

ZA941197A

Other languages

English (en)

Inventor

Sonia J Heiber

Charles D Ebert

Sirish Chandra Dave

Original Assignee

Theratech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-02-22

Filing date

1994-02-22

Publication date

1994-09-19

1994-02-22 Application filed by Theratech Inc filed Critical Theratech Inc

1994-09-19 Publication of ZA941197B publication Critical patent/ZA941197B/xx

Links

229940079593 drug Drugs 0.000 title abstract 6
239000003814 drug Substances 0.000 title abstract 6
239000003623 enhancer Substances 0.000 abstract 3
229920000642 polymer Polymers 0.000 abstract 3
239000003833 bile salt Substances 0.000 abstract 2
210000000214 mouth Anatomy 0.000 abstract 2
102000055006 Calcitonin Human genes 0.000 abstract 1
108060001064 Calcitonin Proteins 0.000 abstract 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
238000004220 aggregation Methods 0.000 abstract 1
230000002776 aggregation Effects 0.000 abstract 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
229960004015 calcitonin Drugs 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
230000008025 crystallization Effects 0.000 abstract 1
150000004676 glycans Chemical class 0.000 abstract 1
229920001477 hydrophilic polymer Polymers 0.000 abstract 1
239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
239000003055 low molecular weight heparin Substances 0.000 abstract 1
229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
229920002521 macromolecule Polymers 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
210000004877 mucosa Anatomy 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
239000004014 plasticizer Substances 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
229920001282 polysaccharide Polymers 0.000 abstract 1
239000005017 polysaccharide Substances 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

Health & Medical Sciences (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA941197A 1993-02-22 1994-02-22 Transmucosal delivery of macromolecular drugs ZA941197B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/027,508 US5346701A (en)	1993-02-22	1993-02-22	Transmucosal delivery of macromolecular drugs

Publications (1)

Publication Number	Publication Date
ZA941197B true ZA941197B (en)	1994-09-19

Family

ID=21838122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA941197A ZA941197B (en)	1993-02-22	1994-02-22	Transmucosal delivery of macromolecular drugs

Country Status (15)

Country	Link
US (2)	US5346701A (fr)
EP (1)	EP0684806B1 (fr)
JP (1)	JP2795749B2 (fr)
KR (1)	KR960700670A (fr)
AT (1)	ATE190216T1 (fr)
AU (1)	AU674571B2 (fr)
CA (1)	CA2156708C (fr)
DE (1)	DE69423342T2 (fr)
DK (1)	DK0684806T3 (fr)
ES (1)	ES2148320T3 (fr)
GR (1)	GR3033601T3 (fr)
NO (1)	NO953279L (fr)
PT (1)	PT684806E (fr)
WO (1)	WO1994018925A1 (fr)
ZA (1)	ZA941197B (fr)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464866A (en) *	1992-08-17	1995-11-07	Alcon Laboratories, Inc.	Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5346701A (en) *	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5639469A (en) *	1994-06-15	1997-06-17	Minnesota Mining And Manufacturing Company	Transmucosal delivery system
WO1996013270A1 (fr) *	1994-10-28	1996-05-09	The Trustees Of The University Of Pennsylvania	Heparine, preparations d'heparine et leurs techniques d'utilisation
US6992107B1 (en) *	1995-03-10	2006-01-31	Photocure Asa	Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US5653987A (en) *	1995-05-16	1997-08-05	Modi; Pankaj	Liquid formulations for proteinic pharmaceuticals
US5766620A (en) *	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) *	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US20040014709A1 (en) *	1996-01-08	2004-01-22	Canji, Inc.	Methods and compositions for interferon therapy
US6392069B2 (en)	1996-01-08	2002-05-21	Canji, Inc.	Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en)	1996-01-08	2006-02-21	Canji, Inc.	Compositions and methods for therapeutic use
US5789244A (en) *	1996-01-08	1998-08-04	Canji, Inc.	Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US5800832A (en) *	1996-10-18	1998-09-01	Virotex Corporation	Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (de)	1996-11-11	1998-05-14	Lohmann Therapie Syst Lts	Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US20040018241A1 (en) *	1997-09-26	2004-01-29	Noven Pharmaceuticals, Inc.	Bioadhesive compositions and methods for topical administration of active agents
WO1999015210A2 (fr) *	1997-09-26	1999-04-01	Noven Pharmaceuticals, Inc.	Compositions bioadhesives et methodes d'administration locale d'agents actifs
US20050048102A1 (en) *	1997-10-16	2005-03-03	Virotex Corporation	Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
CA2320900C (fr)	1998-03-19	2009-10-27	Bristol-Myers Squibb Company	Systeme d'apport a liberation lente biphasique destine a des medicaments a solubilite elevee et procede associe
AU4376199A (en) *	1998-06-26	2000-01-17	Pasteur Merieux Serums Et Vaccins	Mucosal targeting immunisation
US20070072828A1 (en) *	1998-07-24	2007-03-29	Yoo Seo H	Bile preparations for colorectal disorders
US20050158408A1 (en) *	1998-07-24	2005-07-21	Yoo Seo H.	Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) *	1998-07-24	2007-12-04	Seo Hong Yoo	Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) *	2004-10-15	2010-08-10	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
BR9913831A (pt)	1998-09-17	2001-05-29	Bristol Myers Squibb Co	Processo para tratamento de arteriosclerose empregando um inibidor de ap2 e combinação
US7001609B1 (en)	1998-10-02	2006-02-21	Regents Of The University Of Minnesota	Mucosal originated drug delivery systems and animal applications
HUP0103543A2 (hu) *	1998-10-02	2002-01-28	3M Innovative Properties Company	Nyálkahártyán megtapadó hatóanyag bejuttató rendszerek és ezek alkalmazása állatok kezelésére
DE19856101A1 (de) *	1998-12-04	2000-06-08	Labtec Gmbh	Mundhöhlen-Matrixpflaster
WO2000038696A1 (fr) *	1998-12-28	2000-07-06	Allergy Limited, Llc	Utilisation de la cyanocobalamine (vitamine b12) pour le traitement des allergies
US6552024B1 (en)	1999-01-21	2003-04-22	Lavipharm Laboratories Inc.	Compositions and methods for mucosal delivery
US6180682B1 (en)	1999-01-26	2001-01-30	Virgil A. Place	Buccal drug delivery system for use in male contraception
US6284262B1 (en)	1999-01-26	2001-09-04	Virgil A. Place	Compact dosage unit for buccal administration of a pharmacologically active agent
US6117446A (en)	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US7658938B2 (en)	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6353770B1 (en)	1999-05-26	2002-03-05	Levi Strauss & Co.	Apparatus and method for the remote production of customized clothing
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
DE10026699A1 (de)	2000-05-30	2001-12-06	Basf Ag	Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
GB0018527D0 (en) *	2000-07-27	2000-09-13	Photocure Asa	Composition
US6756051B1 (en)	2000-11-15	2004-06-29	Li-Lan H. Chen	Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
US7803392B2 (en) *	2000-12-27	2010-09-28	University Of Kentucky Research Foundation	pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
JP2004536047A (ja)	2001-04-11	2004-12-02	ブリストル−マイヤーズ　スクイブ　カンパニー	糖尿病処置用ｃ−アリールグルコシドのアミノ酸複合体および方法
CN1531436A (zh) *	2001-05-09	2004-09-22	(株)美大富历寿	用于增强粘膜吸收的两亲肝素衍生物制剂
US8765167B2 (en)	2001-10-12	2014-07-01	Monosol Rx, Llc	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20060039958A1 (en) *	2003-05-28	2006-02-23	Monosolrx, Llc.	Multi-layer films having uniform content
US8603514B2 (en)	2002-04-11	2013-12-10	Monosol Rx, Llc	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070154527A1 (en) *	2001-10-12	2007-07-05	Monosoirx, Llc	Topical film compositions for delivery of actives
US11207805B2 (en)	2001-10-12	2021-12-28	Aquestive Therapeutics, Inc.	Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) *	2001-10-12	2008-04-15	Monosol Rx, Llc	Process for making an ingestible film
US8900498B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for manufacturing a resulting multi-layer pharmaceutical film
US7910641B2 (en) *	2001-10-12	2011-03-22	Monosol Rx, Llc	PH modulated films for delivery of actives
US8900497B2 (en)	2001-10-12	2014-12-02	Monosol Rx, Llc	Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en)	2009-08-07	2011-02-10	Monosol Rx, Llc	Sublingual and buccal film compositions
US20190328679A1 (en)	2001-10-12	2019-10-31	Aquestive Therapeutics, Inc.	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en)	2001-10-12	2007-12-06	Fuisz Richard C	Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7666337B2 (en) *	2002-04-11	2010-02-23	Monosol Rx, Llc	Polyethylene oxide-based films and drug delivery systems made therefrom
US7425292B2 (en)	2001-10-12	2008-09-16	Monosol Rx, Llc	Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US10285910B2 (en)	2001-10-12	2019-05-14	Aquestive Therapeutics, Inc.	Sublingual and buccal film compositions
US20100021526A1 (en) *	2001-10-12	2010-01-28	Monosol Rx, Llc	Ph modulated films for delivery of actives
US8663687B2 (en)	2001-10-12	2014-03-04	Monosol Rx, Llc	Film compositions for delivery of actives
US6806381B2 (en) *	2001-11-02	2004-10-19	Bristol-Myers Squibb Company	Process for the preparation of aniline-derived thyroid receptor ligands
US6984645B2 (en) *	2001-11-16	2006-01-10	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
CA2472103A1 (fr) *	2002-01-25	2003-08-07	Santarus, Inc.	Administration par voie muqueuse d'inhibiteurs de la pompe a protons
US8017150B2 (en) *	2002-04-11	2011-09-13	Monosol Rx, Llc	Polyethylene oxide-based films and drug delivery systems made therefrom
US20030194420A1 (en) *	2002-04-11	2003-10-16	Richard Holl	Process for loading a drug delivery device
EP1504525A2 (fr) *	2002-05-14	2005-02-09	Siemens Aktiengesellschaft	Procede pour generer un signal d'emission
WO2003099264A1 (fr) *	2002-05-23	2003-12-04	Umd, Inc.	Compositions et methode d'administration de medicaments par voie transmuqueuse et de cryoprotection
US6995180B2 (en) *	2002-10-23	2006-02-07	Bristol Myers Squibb Company	Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods
TW200504021A (en) *	2003-01-24	2005-02-01	Bristol Myers Squibb Co	Substituted anilide ligands for the thyroid receptor
WO2004066929A2 (fr) *	2003-01-24	2004-08-12	Bristol-Myers Squibb Company	Cycloalkyle contenant des ligands anilide pour le recepteur des hormones thyroidiennes
US7306812B2 (en) *	2003-05-09	2007-12-11	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) *	2003-05-09	2007-10-02	Cephalon, Inc.	Dissolvable backing layer for use with a transmucosal delivery device
US20040241223A1 (en) *	2003-05-27	2004-12-02	David Wong	Oral dosage forms for macromolecular drugs
AU2004245995A1 (en) *	2003-06-04	2004-12-16	Canji, Inc.	Transfection agents
US7459474B2 (en) *	2003-06-11	2008-12-02	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
US7145125B2 (en)	2003-06-23	2006-12-05	Advanced Optical Technologies, Llc	Integrating chamber cone light using LED sources
US6995183B2 (en) *	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) *	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7470397B2 (en)	2003-10-24	2008-12-30	Adhesives Research, Inc.	Disintegratable films for diagnostic devices
AR046778A1 (es) *	2003-11-12	2005-12-21	Phenomix Corp	Compuestos heterociclicos de acido boronico. metodos de obtencion y composiciones farmaceuticas.
US7317109B2 (en) *	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) *	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) *	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US8415298B2 (en)	2004-06-21	2013-04-09	The Board Of Trustees Of The Leland Stanford Junior University Of Stanford	Administration of FGF2 for treamtent of anxiety
JP2008505975A (ja) *	2004-07-12	2008-02-28	フェノミックスコーポレーション	制約されたシアノ化合物
CN101035541B (zh) *	2004-08-30	2012-05-30	柳署弘	溶解的udca在局灶缺血模型中的神经保护作用
CA2518650A1 (fr) *	2004-09-10	2006-03-10	Dimitrios Dimitrakoudis	Formule a base de toxine de clostridium botulinum et methode permettant de perdre du poids
AR051446A1 (es) *	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AU2005295541B2 (en) *	2004-10-15	2011-02-17	Seo Hong Yoo	Methods and compositions for reducing toxicity of a pharmaceutical compound
DE602005025391D1 (de) *	2004-11-01	2011-01-27	Seo Hong Yoo	Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
US7635699B2 (en) *	2004-12-29	2009-12-22	Bristol-Myers Squibb Company	Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) *	2004-12-29	2009-09-15	Bristol-Myers Squibb Company	Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7317024B2 (en)	2005-01-13	2008-01-08	Bristol-Myers Squibb Co.	Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
US7521557B2 (en)	2005-05-20	2009-04-21	Bristol-Myers Squibb Company	Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) *	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7888381B2 (en)	2005-06-14	2011-02-15	Bristol-Myers Squibb Company	Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
US7488725B2 (en)	2005-10-31	2009-02-10	Bristol-Myers Squibb Co.	Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
DK2564864T3 (en)	2005-11-12	2015-04-07	Trustees Of The Leland Board Of	FGF-2 related methods for the diagnosis and treatment of depression
US7592461B2 (en)	2005-12-21	2009-09-22	Bristol-Myers Squibb Company	Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
SE530184C2 (sv) *	2005-12-23	2008-03-18	Kjell Stenberg	Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
CN101370477A (zh) *	2006-01-20	2009-02-18	莫诺索尔克斯有限公司	薄膜连接的包装及其制备方法
US20070238770A1 (en) *	2006-04-05	2007-10-11	Bristol-Myers Squibb Company	Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
CA2648594C (fr) *	2006-04-07	2012-10-16	Merrion Research Iii Limited	Forme pharmaceutique solide par voie orale contenant un activateur
WO2007146234A2 (fr) *	2006-06-09	2007-12-21	Merrion Research Ii Limited	Forme posologique solide à administrer par voie orale contenant un activateur
US7795291B2 (en)	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN103550136B (zh)	2006-07-21	2016-04-13	生物递送科学国际公司	吸收增强的经粘膜递送装置
EP2063864A4 (fr) *	2006-09-20	2012-03-14	Monosol Rx Llc	Film hydrosoluble comestible contenant un agent aromatisant réduisant la mousse
EP2077824A4 (fr) *	2006-09-29	2012-07-18	Monosol Rx Llc	Conditionnement dans lequel un film est incorporé et son procédé de fabrication
US8043829B2 (en) *	2006-10-25	2011-10-25	Amgen Inc.	DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
WO2008057855A2 (fr)	2006-11-01	2008-05-15	Bristol-Myers Squibb Company	Modulateur du récepteur de glucocorticoïdes, ap-1, et/ou activité de nf-kb et leur utilisation
JP2010508358A (ja)	2006-11-01	2010-03-18	ブリストル−マイヤーズスクイブカンパニー	グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用
EP2089355A2 (fr)	2006-11-01	2009-08-19	Brystol-Myers Squibb Company	Modulateurs de recepteur de glucocorticoide, d'activite ap-1 et/ou nf- kappa b, et leur utilisation
JP2010519196A (ja) *	2007-02-15	2010-06-03	ダーマ−ヤングリミテッド	経粘膜送達を高めるための組成物および方法
EP2738257A1 (fr)	2007-05-22	2014-06-04	Amgen Inc.	Compositions et procédés pour produire des protéines de fusion bioactives
EP2008651A1 (fr) *	2007-06-26	2008-12-31	Drug Delivery Solutions Limited	Patch bioérodable
US8309730B2 (en)	2007-11-01	2012-11-13	Bristol-Myers Squibb Company	Nonsteroidal compounds useful as modulators of glucocorticoid receptor AP-1 and/or NF-kappab acitivity and use thereof
JP2011519928A (ja) *	2008-05-07	2011-07-14	メリオン・リサーチ・Ｉｉｉ・リミテッド	ペプチドの組成物及びその調製方法
CN105833420A (zh) *	2008-06-23	2016-08-10	生物递送科学国际公司	多向粘膜给药装置及使用方法
US8106046B2 (en)	2008-06-24	2012-01-31	Bristol-Myers Squibb Company	Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR075613A1 (es) *	2009-02-25	2011-04-20	Merrion Res Iii Ltd	Composicion y suministro de drogas de bifosfonato. metodo de tratamiento
US8475832B2 (en)	2009-08-07	2013-07-02	Rb Pharmaceuticals Limited	Sublingual and buccal film compositions
US9421169B2 (en) *	2009-11-20	2016-08-23	Covidien Lp	Oral dosage forms for delivery of therapeutic agents
EP2504019A2 (fr)	2009-11-25	2012-10-03	ArisGen SA	Composition à libération par voie muqueuse contenant un peptide, un agent de couronne et/ou un contre-ion
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) *	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2011137491A1 (fr) *	2010-05-06	2011-11-10	University Of South Australia	Nouveau système d'administration de médicament
WO2011156711A1 (fr)	2010-06-10	2011-12-15	Schobel Alexander M	Systèmes d'administration de film de nanoparticules
EP2590634B1 (fr)	2010-07-09	2016-03-09	BHV Pharma, Inc.	Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
US9149959B2 (en)	2010-10-22	2015-10-06	Monosol Rx, Llc	Manufacturing of small film strips
JP2014501784A (ja)	2011-01-07	2014-01-23	メリオン・リサーチ・Ｉｉｉ・リミテッド	経口投与用の鉄の医薬組成物
BR112013023674A2 (pt)	2011-03-16	2016-12-13	Amgen Inc	inibidores potentes e seletivos de nav1.3 e nav1.7
EP2526971A1 (fr)	2011-05-25	2012-11-28	ArisGen SA	Administration de médicaments par les muqueuses
ES2660116T3 (es)	2011-08-18	2018-03-20	Biodelivery Sciences International, Inc.	Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
US9901539B2 (en)	2011-12-21	2018-02-27	Biodelivery Sciences International, Inc.	Transmucosal drug delivery devices for use in chronic pain relief
WO2014165277A2 (fr)	2013-03-12	2014-10-09	Amgen Inc.	Inhibiteurs sélectifs et puissants de nav1.7
US9593113B2 (en)	2013-08-22	2017-03-14	Bristol-Myers Squibb Company	Imide and acylurea derivatives as modulators of the glucocorticoid receptor
JP7211704B2 (ja)	2015-01-29	2023-01-24	ノヴォノルディスクアー／エス	Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
US11273131B2 (en)	2016-05-05	2022-03-15	Aquestive Therapeutics, Inc.	Pharmaceutical compositions with enhanced permeation
CA3022840A1 (fr)	2016-05-05	2017-11-09	Aquestive Therapeutics, Inc.	Compositions d'epinephrine a administration amelioree
US12433850B2 (en)	2016-05-05	2025-10-07	Aquestive Therapeutics, Inc.	Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en)	2016-05-05	2025-09-30	Aquestive Therapeutics, Inc.	Enhanced delivery epinephrine compositions
US11318190B2 (en)	2017-05-05	2022-05-03	United States Government As Represented By The Department Of Veterans Affairs	Methods and compositions for treating liver disease
US12478662B2 (en)	2020-01-03	2025-11-25	The United States of America as represented by the Secretary Department of Heath and Human Services	TNAP locally administered for promoting periodontal health
WO2023027006A1 (fr) *	2021-08-27	2023-03-02	学校法人東京理科大学	Activateur de perméation membranaire, procédé d'amélioration de perméation membranaire et procédé d'administration intracellulaire
US20250003978A1 (en)	2021-10-15	2025-01-02	The Regents Of The University Of California	Diagnosis and treatment of anti-pf4 induced thrombocytopenia
EP4422607A4 (fr)	2021-10-25	2025-09-03	Aquestive Therapeutics Inc	Compositions orales et nasales et méthodes de traitement
US20250206796A1 (en)	2022-04-13	2025-06-26	The Regents Of The University Of California	Use of viral il-6 in cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3681754D1 (de) *	1985-04-27	1991-11-07	Nitto Denko Corp	Klebepflaster und arzneimittel fuer die mundhoehle.
GB8723846D0 (en) *	1987-10-10	1987-11-11	Danbiosyst Ltd	Bioadhesive microsphere drug delivery system
US4849224A (en) *	1987-11-12	1989-07-18	Theratech Inc.	Device for administering an active agent to the skin or mucosa
US4948580A (en) *	1988-12-08	1990-08-14	E. R. Squibb & Sons, Inc.	Muco-bioadhesive composition
US4994439A (en) *	1989-01-19	1991-02-19	California Biotechnology Inc.	Transmembrane formulations for drug administration
US5122383A (en) *	1991-05-17	1992-06-16	Theratech, Inc.	Sorbitan esters as skin permeation enhancers
US5346701A (en) *	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs

1993
- 1993-02-22 US US08/027,508 patent/US5346701A/en not_active Expired - Lifetime
1994
- 1994-02-03 CA CA002156708A patent/CA2156708C/fr not_active Expired - Fee Related
- 1994-02-03 JP JP6519014A patent/JP2795749B2/ja not_active Expired - Lifetime
- 1994-02-03 ES ES94908732T patent/ES2148320T3/es not_active Expired - Lifetime
- 1994-02-03 DK DK94908732T patent/DK0684806T3/da active
- 1994-02-03 EP EP94908732A patent/EP0684806B1/fr not_active Expired - Lifetime
- 1994-02-03 AT AT94908732T patent/ATE190216T1/de not_active IP Right Cessation
- 1994-02-03 PT PT94908732T patent/PT684806E/pt unknown
- 1994-02-03 WO PCT/US1994/001372 patent/WO1994018925A1/fr not_active Ceased
- 1994-02-03 DE DE69423342T patent/DE69423342T2/de not_active Expired - Fee Related
- 1994-02-03 KR KR1019950703500A patent/KR960700670A/ko not_active Abandoned
- 1994-02-03 AU AU61716/94A patent/AU674571B2/en not_active Ceased
- 1994-02-22 ZA ZA941197A patent/ZA941197B/xx unknown
- 1994-05-16 US US08/243,415 patent/US5516523A/en not_active Expired - Fee Related
1995
- 1995-08-21 NO NO953279A patent/NO953279L/no not_active Application Discontinuation
2000
- 2000-06-01 GR GR20000401286T patent/GR3033601T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU6171694A (en)	1994-09-14
EP0684806A1 (fr)	1995-12-06
GR3033601T3 (en)	2000-10-31
JPH08507759A (ja)	1996-08-20
NO953279L (no)	1995-10-19
DK0684806T3 (da)	2000-08-14
NO953279D0 (no)	1995-08-21
US5516523A (en)	1996-05-14
ATE190216T1 (de)	2000-03-15
ES2148320T3 (es)	2000-10-16
KR960700670A (ko)	1996-02-24
JP2795749B2 (ja)	1998-09-10
WO1994018925A1 (fr)	1994-09-01
HK1010680A1 (en)	1999-06-25
US5346701A (en)	1994-09-13
DE69423342T2 (de)	2000-10-12
AU674571B2 (en)	1997-01-02
CA2156708C (fr)	2005-05-03
EP0684806B1 (fr)	2000-03-08
CA2156708A1 (fr)	1994-09-01
PT684806E (pt)	2000-08-31
DE69423342D1 (de)	2000-04-13
EP0684806A4 (fr)	1997-04-23

Publication	Publication Date	Title
ZA941197B (en)	1994-09-19	Transmucosal delivery of macromolecular drugs
EP0460020B2 (fr)	1997-09-17	Compositions pour l'administration de medicaments
US5554388A (en)	1996-09-10	Systemic drug delivery compositions comprising a polycationi substance
EP0302772B1 (fr)	1992-09-30	Calcitonin pour administration nasale
AU2002332197B2 (en)	2007-02-15	Nicotine-containing film preparation
EP1722759B1 (fr)	2011-03-09	Composition contenant du chitosane et un phosphate de sucre ou un phosphate de polyol
HK1050135A1 (zh)	2003-06-13	用於促进将药物给予胃的饭後模式药理学诱导
NO178564B (no)	1996-01-15	Framgangsmåte for framstilling av et system for administrering av aktive medikamenter gjennom slimhinner
AU2006327277B2 (en)	2012-12-13	Water-soluble films comprising low-viscosity alginates
JPH06107550A (ja)	1994-04-19	経口抗炎症剤
Ranade	1990	Drug delivery systems: 3A. Role of polymers in drug delivery
JP2802488B2 (ja)	1998-09-24	経鼻吸収用生理活性ペプチド組成物
Bernkop-Schnürch et al.	2005	Thiomers: The next generation of mucoadhesive polymers
AU1469295A (en)	1995-08-01	Low molecular weight hyaluronic acid with peptide or protein
NO860012L (no)	1986-07-07	Preparater med forsinket virkning, fremgangsmaate til deres fremstilling samt tilsvarende middel til human- resp. veterinaermedisinsk anvendelse.
Nakanishi et al.	1998	Use of sodium salt of Carbopol 934P in oral peptide delivery
Rao et al.	2017	Bioadhesion and Factors Affecting the Bioadhesion of Microparticles 1
CA1297627C (fr)	1992-03-17	Polymeres biodegradables pour les preparations de depot a liberation lente ducompose actif
Vetter et al.	2016	Bioadhesive Delivery Systems
WO2024246701A1 (fr)	2024-12-05	Nouvelles combinaisons de principes actifs, compositions les contenant et leur utilisation en thérapie
Vetter et al.	2016	14 Bioadhesive Delivery Systems
HK1010680B (en)	2000-09-01	Transmucosal delivery of macromolecular drugs